Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study.
Roderick C SliekerLouise A DonnellyHugo FitipaldiGerard A BoulandGiuseppe N GiordanoMikael ÅkerlundMathias J GerlEmma AhlqvistAshfaq AliIulian DraganAndreas FestaMichael K HansenDina Mansour AlyMin KimDmitry KuznetsovFlorence MehlChristian KloseKai SimonsImre PavoTimothy J PullenTommi SuvitaivalAsger WretlindEllen BurgessValeriya LyssenkoCristina Legido-QuigleyLeif C GroopBernard ThorensPaul W FranksMark IbbersonGuy A RutterJoline W J BeulensLeendert M 't HartEwan R PearsonPublished in: Diabetologia (2021)
Clusters based on C-peptide instead of HOMA2 measures resemble those based on HOMA2 measures, especially for SIDD, SIRD and MOD. By adding HDL-cholesterol, the MARD cluster based upon HOMA2 measures resulted in the current clustering into two clusters, with one cluster having high HDL levels. Cross-validation between cohorts showed generally a good resemblance between cohorts. Together, our results show that the clustering based on clinical variables readily measured in the clinic (age, HbA1c, HDL-cholesterol, BMI and C-peptide) results in informative clusters that are representative of the original ANDIS clusters and stable across cohorts. Adding HDL-cholesterol to the clustering resulted in the identification of a cluster with very slow glycaemic deterioration.